<DOC>
	<DOCNO>NCT02653118</DOCNO>
	<brief_summary>Protocol V503-021 long-term follow-up study V503-001 base study ( NCT00543543 ) evaluate safety , immunogenicity , long-term effectiveness V503 vaccine prevent cervical cancer relate precancers cause human papillomavirus ( HPV ) type 16 , 18 , 31 , 33 , 45 , 52 , 58 . Because high retention V503-001 participant Nordic country , highly efficient screen surveillance system , study V503-021 evaluate participant V503-001 site Denmark , Norway , Sweden . The hypothesis test V503 vaccine remain effective least 14 year start vaccination .</brief_summary>
	<brief_title>Long-term Follow-up Broad Spectrum Human Papillomavirus ( HPV ) Vaccine Study Women ( V503-021 )</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<criteria>Randomized V503001 ( NCT00543543 ) study Denmark , Norway , Sweden site participate study receive either select dose formulation V503 GARDASIL Age 16 26 year time enrollment study V503001 Agrees allow passive followup , analysis biopsy specimen , future contact National Registry Study Centers , serum collection There exclusion criterion</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>